Lymphocyte functions triggered by antigen recognition and costimulation signals are associated with a rapid and intense cell division, and hence with metabolism adaptation 1 . The nucleotide cytidine 59 triphosphate (CTP) is a precursor required for the metabolism of DNA, RNA and phospholipids 2-4 . CTP originates from two sources: a salvage pathway and a de novo synthesis pathway that depends on two enzymes, the CTP synthases (or synthetases) 1 and 2 (CTPS1 with CTPS2); the respective roles of these two enzymes are not known 5-7 . CTP synthase activity is a potentially important step for DNA synthesis in lymphocytes 8, 9 . Here we report the identification of a lossof-function homozygous mutation (rs145092287) in CTPS1 in humans that causes a novel and life-threatening immunodeficiency, characterized by an impaired capacity of activated T and B cells to proliferate in response to antigen receptor-mediated activation. In contrast, proximal and distal T-cell receptor (TCR) signalling events and responses were only weakly affected by the absence of CTPS1. Activated CTPS1-deficient cells had decreased levels of CTP. Normal T-cell proliferation was restored in CTPS1-deficient cells by expressing wildtype CTPS1 or by addition of exogenous CTP or its nucleoside precursor, cytidine. CTPS1 expression was found to be low in resting T cells, but rapidly upregulated following TCR activation. These results highlight a key and specific role of CTPS1
Lymphocyte functions triggered by antigen recognition and costimulation signals are associated with a rapid and intense cell division, and hence with metabolism adaptation 1 . The nucleotide cytidine 59 triphosphate (CTP) is a precursor required for the metabolism of DNA, RNA and phospholipids [2] [3] [4] . CTP originates from two sources: a salvage pathway and a de novo synthesis pathway that depends on two enzymes, the CTP synthases (or synthetases) 1 and 2 (CTPS1 with CTPS2); the respective roles of these two enzymes are not known [5] [6] [7] . CTP synthase activity is a potentially important step for DNA synthesis in lymphocytes 8, 9 . Here we report the identification of a lossof-function homozygous mutation (rs145092287) in CTPS1 in humans that causes a novel and life-threatening immunodeficiency, characterized by an impaired capacity of activated T and B cells to proliferate in response to antigen receptor-mediated activation. In contrast, proximal and distal T-cell receptor (TCR) signalling events and responses were only weakly affected by the absence of CTPS1. Activated CTPS1-deficient cells had decreased levels of CTP. Normal T-cell proliferation was restored in CTPS1-deficient cells by expressing wildtype CTPS1 or by addition of exogenous CTP or its nucleoside precursor, cytidine. CTPS1 expression was found to be low in resting T cells, but rapidly upregulated following TCR activation. These results highlight a key and specific role of CTPS1 in the immune system by its capacity to sustain the proliferation of activated lymphocytes during the immune response. CTPS1 may therefore represent a therapeutic target of immunosuppressive drugs that could specifically dampen lymphocyte activation.
We initially studied two unrelated families (family 1 and 2) originating from the northwest region of England, whose four children suffered from severe and recurrent Epstein-Barr virus (EBV) infection, in whom known primary immunodeficiencies have been excluded 10 (Fig. 1a and Table 1 ). Four additional patients (family 3 to 5) originating from the same geographical area were identified thereafter (Methods). All patients had early onset of severe chronic viral infections, mostly caused by herpes viruses, including EBV and varicella zooster virus (VZV) and also suffered from recurrent encapsulated bacterial infections, a spectrum of infections typical of a combined deficiency of adaptive immunity (CID) 11 ( Table 1 and data not shown). Two patients (P4 and P5) had EBV-driven B-cell non-Hodgkin lymphoma. Overall, the clinical phenotype is severe with 3 patients having died. Six of 8 patients have undergone haematopoietic stem cell transplantation. Of note, none of the patients had extra-haematopoietic manifestations ( Table 1) .
Immunological investigations showed that most of patients had variable lymphopenia which was exacerbated during infection episodes with inversed CD4:CD8 T-cell ratio, whereas other blood cell counts were usually normal (Extended Data Table 1 and data not shown). Their immunoglobulin levels were normal or elevated with increased IgG but low IgG2 levels with low antibody titres to Streptococcus pneumoniae. Further analyses were performed in patient P1. 2 showing naive CD4 1 T-cell lymphopenia, increased numbers of effector memory T cells, low numbers of memory CD27 1 B cells, a complete absence of both invariant T cell populations (CD3 1 Va24 1 Vb11 1 ) iNKT and (CD3 1 CD161 Hi Va7.2 1 ) MAIT cells, as well as an impaired PHA-and antigen-induced proliferation of peripheral blood mononuclear cells (PBMCs) (Extended Data Table 2 ).
To identify the gene defect underlying the immunodeficiency in these patients, we performed whole-exome sequencing (WES) in three patients (P1.1, P1.2 and P2.1). Intersection of the genetic variations found in the three patients pointed to an unique common homozygous G to C mutation in the CTPS1 gene encoding the CTP synthase 1 at position 41475832 in chromosome 1 with an assigned rsID (rs145092287) in the dbSNP database ( Fig. 1b and Extended Data Fig. 1a, b ). CTPS1 encodes a 67-kDa protein containing a CTP synthetase domain and a glutamine amide transfer domain promoting the formation of CTP from UTP and glutamine 12 . The identified mutation affects a splice donor site at the junction of intron 17-18 and exon 18 (IVS18-1 G to C) leading to the expression of an abnormal transcript lacking exon 18 (Extended Data Fig. 1b, c ). This splice mutation was found to be deleterious because CTPS1 protein expression could not be detected in lysates of EBVtransformed B cells and T-cell blasts from patients (Figs 1c and 2c and Extended Data Fig. 2 ). In contrast, CTPS2 was expressed normally in patient cell lysates. In the five affected families, all patients were homozygous for the IVS18-1 G to C mutation and all parents and tested healthy siblings were heterozygous carriers ( Fig. 1a , b and data not shown). Sequencing of a cohort of 752 healthy individuals from the northwest of England gave an estimated frequency of homozygosity of 1:560,000. This represents more than a tenfold increase compared to the frequency estimated from available exome databases. WES data and analysis of polymorphic microsatellite markers in all patients revealed a common region of homozygosity of 1.1 Mb surrounding the IVS18-1 G to C mutation (Supplementary Information). All these data were indicative of a founder effect. These observations led us to conclude that the immunodeficiency resulting from the CTPS1 mutation in these patients could be primarily associated with a T-cell immunodeficiency.
We next examined CTPS1 expression in normal tissues. CTPS1 mRNA expression was comparable between the different tissues, except for T cells in which CTPS1 expression was strongly upregulated after cell activation in response to TCR-CD3 and CD28 co-stimulation ( Fig. 1d ). Interestingly, in lysates from resting non-activated T-cell blasts and T cells from PBMCs, CTPS1 protein was almost undetectable ( Fig. 2a-d) .
In contrast, CTPS2 expression was readily detected. Activation of T cells by anti-CD3 antibody or phorbol 12-myristate 13-actate (PMA) and ionomycin stimulations induced CTPS1 protein expression, whereas activation with IL-2 and/or IL-15 resulted in only a weak effect. Under the same experimental conditions, CTPS2 expression was also induced but to a lesser extent. In TCR-CD3-stimulated T-cell blasts, CTPS1 protein expression was enhanced from 12 h and persisted for up to 96 h as a consequence of CTPS1 gene transcription activation (Fig. 1d , inset and Fig. 2b ). As expected, no expression of CTPS1 was detected in T-cell blasts from the CTPS1-deficient patient (P1.2) contrasting with detection of CTPS1 mRNA and suggesting protein instability ( Fig. 2c and Extended Data Fig. 1c ). These data indicate that T-cell activation through the TCR results in a rapid and sustained CTPS1 protein expression. Of note, in B cells activated by anti-BCR and CpG, IL-4 and CD40L or PMA and ionomycin, CTPS1 was also found to be upregulated ( Fig. 2d and Extended Data Fig. 3a, b ).
To further characterize the consequences of the CTPS1 deficiency in T cells, we investigated proximal T-cell activation signals as well as late responses. CTPS1-deficient T cells exhibited normal early and late responses with the exception of ERK1/2 phosphorylation and CD25 and CD69 upregulation which were found to be decreased (Extended Data Fig. 4 ). Basal and activation-induced cell death was also slightly increased (Extended Data Fig. 4g ). These data suggest that CTPS1 deficiency had limited consequences in signalling downstream of TCR-CD3. Because the pool of CTP is potentially a limiting factor for DNA synthesis 8, 13 , we Fig. 6 ). Defective proliferation of CTPS1-deficient T cells was associated with a lack of cell cycle progression as a majority of cells were arrested in the G1 phase ( Fig. 2g ). Proliferation of CTPS1deficient B cells activated by anti-BCR and CpG was also found to be defective, whereas that of IL-2-activated natural killer cells seemed to be less affected ( Fig. 2h and Extended Data Fig. 5b ). Downregulation of CTPS1 expression in control T cells, by lentiviral transduction of two distinct short hairpin RNA (shRNA) together with a GFP reporter gene, resulted in a specific decrease in the CD3-mediated proliferation of GFP-positive cells (Fig. 3a) . No changes in proliferation were detected in non-targeted GFP-negative cells or in cells targeted with a scramble shRNA. The diminished proliferation resulting from the inhibition of CTPS1 expression led to a selective cell growth disadvantage with a decreased number of GFP targeted cells over time (middle panel). A similar decrease in proliferation rate was also observed in the Jurkat T-cell line in which CTPS1 expression was downregulated (Extended Data Fig. 7 ).
Together, these results indicate that CTPS1 deficiency causes a defect in T-cell proliferation in response to TCR-CD3 activation. To formally prove the causal relationship between CTPS1 deficiency and defective T-cell proliferation, we carried out reconstitution experiments with wildtype CTPS1 or by direct addition of CTP or its cytidine precursor that acts on CTP levels through the salvage pathway. Expression of ectopic CTPS1 in CTPS1-deficient T cells fully restored proliferation upon CD3 stimulation ( Fig. 3b ) and enabled cells to expand selectively as shown by the accumulation of GFP-positive cells expressing CTPS1 ( Fig. 3c , left panels). No such effect was detected in CTPS1-deficient cells transduced with an empty vector or in control cells transduced with the CTPS1containing vector.
Proliferation and CD25 expression of CTPS1-deficient cells also recovered to a normal level by addition of CTP or cytidine ( Fig. 3d and data not shown). In contrast, addition of a mix of UTP, GTP and ATP or uracil, guanosine and adenosine did not result in increased proliferation of CTPS1-deficient cells. To determine the influence of the CTPS1 defect on the de novo pyrimidine synthesis pathway, we measured the incorporation of carbon from [ 14 C]aspartate into nucleic acids of activated CTPS1-deficient T cells, which is a specific assay for de novo pyrimidine synthesis 14 ]aspartate in CTPS1-deficient cells, thus demonstrating that the de novo CTP synthesis pathway is impaired in the absence of CTPS1. Deazauridine, an analogue of UTP and a known inhibitor of CTP synthetase activity 15 completely blocked T-cell proliferation of control cells in response to CD3 activation without affecting proximal TCR-CD3-mediated responses, similar to results observed in CTPS1-deficient cells ( Fig. 3f and data not shown). As expected, inhibition of T-cell proliferation by deazauridine was fully reverted by addition of cytidine and partially by uridine, but not by adenosine or guanosine. Analysis of nucleotides pools in activated CTPS1-deficient T-cell blasts and CTPS1-deficient B/EBV cell lines revealed decreased levels of CTP, as also observed in activated normal cells treated with deazauridine ( Fig. 3g, h ). Defective CTPS1 expression or addition of deazauridine also led to reduced pools of ATP, GTP and UTP in activated T cells (Extended Data Fig. 8 ) suggesting interconnection in the nucleotide pools 16 . In contrast, CTP as well as ATP, GTP and UTP were found to be normal or increased in resting CTPS1-deficient T cells as the salvage pathway is suggested to be predominant in quiescent cells 9, 17 . Expression of wild-type CTPS1 in CTPS1-deficient B/EBV cell lines restored levels of CTP comparable to control cells and conferred a selective growth advantage to cells ( Fig. 3h , i).
This study reveals a critical role for CTPS1 in promoting the proliferation of T cells following their activation. However, proliferation of B cells was also found to be dependent on CTPS1. This may directly participate in the susceptibility to encapsulated bacterial infections seen Anti-CTPS2
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in CTPS1-deficient patients and account for the low titres of S. pneumoniae antibodies as it is a T-cell-independent B-cell response. The role of CTPS1 in B cells could be different or/and less important than in T cells. Of note, CTPS1-deficient B cells preserve an intact capacity to expand upon transformation by EBV and patients had normal immunoglobulin levels and/or elevated IgG. Decreased expansion of natural killer cells and low numbers of iNKT and MAIT cells might also contribute to the CTPS1 immunodeficiency as these cells have been proposed to have a role in a broad range of immune responses including anti-EBV immunity [18] [19] [20] [21] . The finding that CTPS1-deficiency causes no other significant clinical consequences favours a redundancy with CTPS2 activity in other cell lineages and tissues. Interestingly, pyrimidine pools including CTP have been previously shown to be strongly expanded in PHA-stimulated T cells by de novo pathways including increased CTPS activity 8, 9 . The induction of CTPS1 expression in activated T cells reported here thus appears as the major determinant of CTP pool increase. Indeed, proliferation of CTPS1-deficient T cells was restored to normal levels by addition of CTP. The exact mechanism(s) by which TCR signalling induces a rapid expression and activation of CTPS1 in T cells remains to be determined, although we showed that the ERK pathway is required, as well as tyrosine phosphorylation signals (Extended Data Fig. 3c ). It is interesting to note that T-cell differentiation does not appear to be severely impaired by CTPS1 deficiency, suggesting that CTP pools in thymocytes may originate from the nucleoside salvage pathway and/ or the CTPS2 activity 8, [22] [23] [24] . Notably, CTPS1 activity is critical for the intense cell division induced by antigenic stimulation as exemplified by massive proliferation and expansion of CD8 1 T cells during viral infections 25, 26 .
In the absence of CTPS1, we showed that de novo pyrimidine synthesis pathway is impaired but not totally abrogated. This residual activity is probably dependent on CTPS2. Recently, the de novo pyrimidine synthesis pathway was shown to be dependent on post-transcriptional regulation by mTORC1 and S6 protein (S6K) kinases that activate the first enzymatic steps required for pyrimidine synthesis 14, 27, 28 . Thus, distinct regulatory mechanisms control de novo pyrimidine synthesis. Based on the present study, CTPS1-mediated tuning of CTP synthesis in lymphocytes appears to be a key element in enabling adaptive immune responses. If CTPS1-specific inhibitors can be designed, they would potentially be highly specific immunosuppressive drugs able to inhibit auto-or allogenic-specific T-cell and B-cell responses without additional toxicity given the lymphocyte specificity of the CTPS1-deficiency phenotype. In conclusion, our results provide the first in vivo evidence of a role of the de novo pyrimidine synthesis pathway as a critical step for proliferation of T and B lymphocytes when activated by antigens.
METHODS SUMMARY
Informed consent was obtained from donors, patients and families of patients. The study and protocols conform to the 1975 declaration of Helsinki as well as to local legislation and ethical guidelines. See Methods for full experimental procedures. In several experiments, data are expressed as means 6 standard deviation (s.d.) denoted by the error bars. P values were calculated by two-tailed Student's t-test.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cohorts of patients.
Beside the four initially identified patients, four additional patients were identified by screening 10 patients (9 families) originating from the northwest of England with severe chronic viral infections, mostly caused by herpes viruses, including EBV and VZV. Furthermore, 24 patients (24 families) originating from different geographical areas with the same phenotype were also tested for all exons of CTPS1 in order to identify other mutations and none was found to be a carrier of CTPS1 mutations. Exome sequencing and analysis. Exome capture was performed according to the manufacturer's protocol using the Illumina TruSeq exome enrichment kit and sequencing of 100 bp paired-end reads on an Illumina HiSeq. Approximately 10 Gb of sequence were obtained for each subject such that 90% of the coding bases of the exome defined by the consensus coding sequence (CCDS) project were covered by at least 10 reads. Adaptor sequences and quality trimmed reads were removed using the Fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) and a custom script was then used to ensure that only read pairs with both mates present were subsequently used. Reads were aligned to hg19 with BWA31, and duplicate reads were marked using Picard (http://picard.sourceforge.net/) and excluded from downstream analyses. Single nucleotide variants (SNVs) and short insertions and deletions (indels) were determined using SAMtools (http://samtools.sourceforge.net/) pileup and varFilter32 with the base alignment quality (BAQ) adjustment disabled, and they were then quality filtered to require at least 20% of reads supporting the variant call. Variants were annotated using both ANNOVAR33 and custom scripts to identify whether they affected protein coding sequences, and whether they had previously been seen in the dbSNP, the 1000 Genomes data set (1,092 genomes), or in approximately 2,073 exomes previously sequenced at our centre. A variant detected in a patient was considered to be a candidate mutation if it had not been reported or had a frequency below 0.001% in the three databases indicated above. At the time the homozygous G to C mutation in CTPS1 (at position chr1:41475832) was identified by WES in the three patients (P1.1, P1.2 and P2.1), it was not described as a dbSNP or assigned to a rsID. Afterwards, this mutation has been identified in the NHLBI GO Exome Sequencing Project (http://evs.gs.washington.edu/EVS/) with the assigned rsID: rs145092287. In the NHLBI GO Exome Sequencing Project, the rs145092287 is present three times in a heterozygous status among 4,300 genomes from an European-American population and not found in the 2,203 genomes of an African-American population. The rs145092287 was not found in a homozygous or heterozygous status in other available genome databases (NCBI, 1000 Genomes project and the 3,519 genomes of our centre). Homozygosity regions around the rs145092287 were determined in the exomes by looking at the homozygous variations. Between the positions chr1:40737516 (rs6677717) and chr1:42008077 (rs 63729761) a succession of 97 homozygous variations (without heterozygous variations) was found to be shared by the three patients. Genomic DNA sequencing. Genomic DNA from peripheral blood cells, EBV-B cell lines and/or fibroblasts of patients, their parents, and other family members was isolated according to standard methods. Genomic DNAs of 752 healthy control subjects born in the northwest of England were obtained from the UK 1958 Birth Cohort (http://www2.le.ac.uk/projects/birthcohort). The estimated frequency of the CTPS1 mutation in the populations was calculated according to the Hardy-Weinberg law. Oligonucleotide primers flanking the 39 region of intron 17-18 and exon 18 of CTPS1 were used to amplify genomic DNA: forward 59-AGAGTTGGT GGTAGGGTGTGTGAC-39 and reverse 59-CTTGCAATCGCAGTGTGTTATC AC-39. PCR products were amplified using high fidelity Platinum Taq DNA Polymerase (Invitrogen) according to the manufacturer's recommendations, purified with the QIAquick gel extraction kit (Qiagen) and sequenced using the ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit (PerkinElmer) according to the manufacturer's recommendations. All collected sequences were analysed using 4peaks software (Version 1.7.2; A. Griekspoor and T. Groothuis, http://nucleobytes. com/index.php/4peaks). Analysis of microsatellite markers. Microsatellite markers were genotyped using UniSTS sequences and mapping information available from the NCBI (http://www. ncbi.nlm.nih.gov). Genomic DNA from patients was used as templates to amplify by PCR with specific fluorescent labelled oligonucleotides, the polymorphic repeats corresponding to the microsatellite markers. PCR products were evaluated using an ABI 3100 DNA Fragment Analyzer (Applied Biosystems), and data were analysed using Genescan and Genotyper software (Applied Biosystems). Gene expression analysis. Total RNA was isolated from EBV-B cell and activated T-cell blasts of P1.2, P2.1 patients and control donors using the RNeasy Mini kit (Qiagen). The samples were depleted of genomic DNA and reverse transcription was performed using Superscript II First Strand Synthesis System (Invitrogen). cDNAs were used as a template to perform PCR amplifications of exon 15 to exon 19 of CTPS1 or exon 4 of actin with the following primers using standard protocols: CTPS1 forward primer: 59-GAGAGGCACCGCCACCGATTTG-39, CTPS1 reverse primer: 59-GCCAGTACACGTGATGGGACATGC-39, actin forward primer: 59-CTCCTTAATGTCACGCACGAT-39; actin reverse primer: 59-CTCCTTAAT GTCACGCACGAT-39. PCR to amplify full length CTPS1 cDNAs from control and patients cells were also performed using the following primers, forward primer: 59-AGCTCTGTCGCTGACGGGAGGAT-39 (exon1); reverse primer: 59-GCCA GTACACGTGATGGGACATGC-39 (exon 19). PCR products were verified by sequencing revealing the expression of an abnormal CTPS1 transcript lacking exon 18 in patients' cells. Multiple tissue cDNA panels from Ozyme (Human MTC panel I, II and Human Immune Sytem MTC panel) were analysed for CTPS1 and CTPS2 gene expression by qRT-PCR. Gene expression assays were performed with Assayson-Demand probe and primer combinations (CTPS1, Hs01041858; CTPS2, Hs00219845; GAPDH, Hs027558991) from Applied Biosystem labelled with 6carboxy-fluorescein (FAM) dye, and universal reaction mixture. Real time quantitative PCRs for GAPDH, CTPS1 and CTPS2 were performed in triplicate using a LightCycler VIIA7 System (Roche). Expression levels were determined by relative quantification using the comparative threshold cycle method 2 DDCt in which DDCt is determined as followed: (Ct target gene -Ct reference gene ) target tissue 2 (Ct target gene -Ct reference gene ) calibrator tissue. The results shown in arbitrary units (a.u.) have been normalized to GAPDH gene expression and are presented as the relative change in gene expression normalized against the calibrator sample corresponding to leukocyte tissue. Cell culture and stimulation. Peripheral blood mononuclear cells (PBMCs) collected from patients and healthy donors were isolated by Ficoll-Paque density gradient (Lymphoprep, Proteogenix) from blood samples using standard procedures. Expansion of T-cell blasts were obtained by incubating PBMCs for 72 h with phytohaemagglutinin (PHA) (2.5 mg ml 21 , Sigma-Aldrich) in RPMI 1640 GlutaMax medium (Invitrogen) supplemented with 5% human male AB blood group serum (BioWest), penicillin (100 U ml -1 ) and streptomycin (100 mg ml 21 ). After 3 days, dead cells were removed by Ficoll-Paque density gradient and blasts were maintained in culture with IL-2 (100 U ml 21 ). For proliferation and cell cycle analyses, blasts were washed and cultured without IL-2 for 72 h to synchronize the cells. Blasts or PBMCs were then cultured during 4 to 6 days in complete medium alone or in the presence of 0.1, 1 or 10 mg ml 21 coated anti-CD3 antibody (clone OKT3, eBiosciences), anti-CD3/CD28-coated beads (Invitrogen), PHA (2.5 mg ml 21 , 10 25 M ionomycin (Sigma-Aldrich) plus 10 27 M phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich), Candidin (5 mg ml 21 , Bio-Rad), tetanus toxoid (1 to 8,000 dilution, Statens Serum Institute) or tuberculosis antigen (50 mg ml 21 , Statens Serum Institute). Proliferation and cell cycle were analysed at the indicated time points. Then 40 mM of 3-Deazauridine (DAZ, Sigma-Aldrich) was added for 12 h before the stimulation. In complementation experiments, blasts were incubated with 100 mM of CTP, UTP, GTP or ATP (New England Biolabs) separately or in combination, or with 200 mM of cytidine, uridine, guanosine or adenosine (Sigma-Aldrich) separately or in combination 12 h before the stimulation. For dosage of nucleotides, blasts were deprived of IL-2 for 72 h before stimulation or not with anti-CD3/CD28coated beads for 48 h and cell lysates were prepared. Jurkat cells 29 , 293-T cells and B EBV cell lines from patients were cultured in RPMI 1640 GlutaMax medium supplemented with 10% heat-inactivated fetal calf serum (Gibco), penicillin (100 U ml 21 ) and streptomycin (100 mg ml 21 ). Cells were free of mycoplasma contamination. Proliferation and cell cycle assays. Cell proliferation was monitored by labelling cells with the cell trace violet dye (CellTrace violet proliferation kit, Invitrogen) or CFSE (5 mM, Invitrogen) before stimulation, according to the manufacturer's instructions. After 4 or 6 days of culture, cells were collected and CellTrace violet or CSFE fluorescence dilution was assessed by flow cytometry. The division index of proliferation was calculated using FlowJo software (Tree Star) and corresponds to the average number of cell divisions per cell including the undivided peak. T-cell responses within total PBMCs were also measured by [ 3 H]thymidine incorporation after 6 days of stimulation. A total of 0.074 MBq ml 21 of [ 3 H]thymidine was added during the last 18 h of stimulation. Cell proliferation was determined by c.p.m. of [ 3 H]thymidine incorporated in cells that were counted with TopCount NXT beta counter (PerkinElmer). Cell cycle analysis was determined by measuring the incorporation of the nucleoside analogue 5-ethynyl-2-deoxyuridine (EdU) into newly synthesized DNA, according to the manufacturer's instructions (Click-iT EdU, Invitrogen) after 48 h of anti-CD3 stimulation. EdU incorporation in cells was measured following conjugation of EdU to azide-modified Alexa Fluor 647 dye. Cells were analysed by flow cytometry with a FACS-Canto II flow cytometry system (BD Biosciences). Nucleic acids and de novo pyrimidine synthesis assays. PBMCs were stimulated in the presence of 1 mg ml 21 coated anti-CD3 antibody (clone OKT3, eBiosciences) or 2.5 mg ml 21 PHA (Sigma-Aldrich) for 3 days or in the presence of candidin (5 mg ml 21 , Bio-Rad), tetanus toxoid (1 to 8,000 dilution, Statens Serum Institute) or PPD (tuberculin) (50 mg ml 21 
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proliferation of CTPS1-deficient cells that required 50 mM. Cells were collected with a Filter Mate harvester (PerkinElmer) on filters for labelled cell assays (Unifilter plates, PerkinElmer) that retain nucleic acids and filters were then washed. Radioactivity (c.p.m.) on filters (corresponding to radiolabelled compounds incorporated in nucleic acids) was measured by liquid scintillation counting with Top-Count NXT beta counter (PerkinElmer). Apoptosis assay. Apoptosis was determined by evaluating phosphatidylserine (PS) exposure in the outer leaflet of the cytoplasmic membrane with PE-conjugated annexin-V in combination with 7-AAD Viaprobe (Apoptosis Detection Kit I, BD) 12 h after stimulation with coated-OKT3 (0.1, 1 or 10 mg ml 21 ). Apoptosis was based on the percentage of annexin V 1 /7AAD 2 cells to exclude necrotic cells. Cells were analysed by flow cytometry. Cytokine production and degranulation. For intracellular staining of cytokines, cells were stimulated overnight with PMA and ionomycin or anti CD3/CD28 beads in the presence of brefeldin A (GolgiPlug, BD). Cells were then fixed and permeabilized using the BD cytofix/cytoperm plus kit (BD Pharmingen) according to the manufacturer's instructions. Cells were labelled with PE-anti-IL-2 (rat IgG2a, MHQ1-17H12), PE/Cy7-anti-TNF-a (mouse IgG1; MAb11), APC-anti-IFN-c (mouse IgG1, 4S.B3) and isotype-matched monoclonal antibodies purchased from Bio-Legend and analysed by flow cytometry. Degranulation was determined by analysis of the expression of CD107/LAMP, a marker of the exocytosis of lytic granules. Blasts were stimulated for 3 h in the presence of 0.3, 3 or 30 mg ml 21 coated-OKT3 and simultaneously labelled with eFluor660-anti-CD107a (mouse IgG1; eBioH4A3), eFluor660-anti-CD107b (mouse IgG1; eBioABL-93) or isotype matched monoclonal antibodies purchased from eBiosciences. Thereafter, cells were collected, washed and stained with FITC-anti-CD3 and PE-anti-CD8 monoclonal antibodies and analysed by flow cytometry. Immunoblotting and analysis of CTPS1 protein expression. Cells (5 3 10 6 cells per ml) were stimulated by anti-CD3 antibody (1 mg ml 21 ) crosslinking with a rabbit anti-mouse IgG (2 mg ml 21 ) or anti CD3/CD28 beads for the indicated time periods. Cells were then lysed in 1% NP40, 50 mM Tris pH 8, 150 mM NaCl, 20 mM EDTA, 1 mM Na 3 VO 4 , 1 mM NaF and complete protease inhibitor cocktail (Roche), as previously described 30 . Protein concentrations were quantitated by BCA assay (BIO-RAD). Then 80 mg of proteins were separated by SDS-PAGE and transferred on PVDF membranes (Millipore). Membranes were blocked with milk or BSA before incubation with antibodies. The following monoclonal antibodies and rabbit polyclonal antibodies were used for immunoblotting: anti-PLC-c1 (#2822S), anti-phosphorylated PLC-c1 (#2821S), anti-phosphorylated ERK1/2 (clone E10, #9106S), anti-ERK1/2 (#4695S) anti-phosphorylated IkBa (clone 5A5, #9246S), anti-phosphorylated PKCtheta (#9377S), NFkB (clone D14E12) anti-phosphorylated AKT (Serine 473, clone 587F11) and anti-phosphorylated tyrosine (4G10) purchased from Cell Signaling Technology and rabbit polyclonal antibodies anti-actin (#A2066) and anti-CTPS1 raised against the residues 341 to 355 (#SAB111071) or 416-430 (#SAB111072) and anti-CTPS2 (#HPA017437) purchased from Sigma-Aldrich. Anti-CTPS1 rabbit polyclonal antibodies (K-21) from Santa Cruz were also tested. Membranes were then washed and incubated with anti-mouse or antirabbit HRP-conjugated secondary antibodies from Cell Signaling and GE Healthcare, respectively. Pierce ECL western blotting substrate was used for detection. For inhibition assays of the signalling pathways after TCR-CD3 activation, cells have been stimulated with anti-CD3/CD28 beads for 48 h in the presence of 100 nM of the MAPK/ERK inhibitor PD0325901, 10 mM of the Src family protein tyrosine kinase inhibitor PP1, 10 mM of the Src family protein tyrosine kinase inhibitor PP2, 10 mM of the selective Ca 21 chelator 1,2-bis-(2-aminophenoxy) ethane-N,N,N',N'tetraacetic acid tetra(acetoxymethyl) ester (BAPTA/AM), 10 mM of the IkBa phosphorylation inhibitor Bay 11-7085 or 10 mM of PI3Kdelta inhibitor IC87114. All were from Sigma-Aldrich, except IC87114 from Calbiochem. The concentrations used were typical and previously reported. After 48 h incubation with the different inhibitors, cell viability was verified and was more than 90% in each condition. The activity and the selectivity of the inhibitors was verified in parallel by immunoblotting for phospho-tyrosine (for PP1 and PP2), IkBa phosphorylation (for Bay 11-7085), ERK phosphorylation (for PD0325901) and AKT phosphorylation (for IC87114) (data not shown). Calcium flux analysis. Ca 21 responses were assessed by flow cytometry, as previously described 31 . Briefly, cells were loaded with 5 mM Indo-1 a.m. (Molecular Probes), washed, incubated with anti-CD4-APC and anti-CD8-PE monoclonal antibodies, stimulated by anti-CD3 antibody (0.125 mg ml 21 ) crosslinking with F(ab9) 2 rabbit anti-mouse IgG (10 mg ml 21 ) and then incubated with ionomycin (1 mM). Cells were analysed with a FACSAria flow cytometer (BD Biosciences). Ca 21 flux data were obtained using kinetic analyses of FlowJo software package (Tree Star). Intracellular Ca 21 levels correspond to the normalized ratio of Ca 21 -bound to Ca 21free Indo-1 fluorescence and are plotted as a function of time. Plasmid constructs, cell transfections and infections. A full-length cDNA encoding wild-type CTPS1 and a full length cDNA encoding the mutant CTPS1D18 were obtained by RT-PCR from control blasts and blasts from patient 1.2 respectively using the forward 59-CGGGATCCCACCATGAAGTATATTCTGGTT-39 and reverse 59-CCGCTCGAGTCAGTCATGATTTATTGA-39 (for wild type) and 59-CCG CTCGAGTTAAAGAAAGTCTCCAAGC-39 (for CTPS1D18) specific primers. The cDNAs were verified by sequencing and inserted into a bicistronic lentiviral expression vector encoding the green fluorescent protein (GFP) as a reporter (pLenti7.3/ V5-TOPO, Invitrogen). Viral particles for infection were obtained by co-expression of the lentiviral vector containing CTPS1 with third-generation lentiviral plasmids containing Gag-Pol, Rev and the G protein of the vesicular stomatitis virus (VSVG) into HEK 293T using calcium phosphate. Viral supernatants were collected every 12 h on 2 consecutive days, starting 48 h after transfection, and viral particles were concentrated by ultracentrifugation at 49,000g for 1.5 h at 12 uC. Cells were infected with viral particles at a minimal titre of 10 7 tranducing units per ml and 48 h after infection, cells were deprived of IL-2 during 72 h for proliferation assays. To assess the selective advantage of GFP expression during long-term expansion, blasts were re-stimulated with anti-CD3/CD28 beads (Invitrogen) every 48 h during 8 days. For CTPS1 gene knockdown, blasts or Jurkat cells were infected at day 3 of PHA stimulation with the pLKO.1 lentiviral vector containing a CTPS1-specific shRNA (OpenBiosystems, nuTRCN0000045349 and nuTRCN0000045350) or a scrambled shRNA in which the puromycin resistance gene was replaced by the GFP gene. Proliferation was analysed in GFP 1 and GFP 2 blasts after 4 days of stimulation with anti-CD3/CD28 beads as previously described. For survey of loss of GFP expression in long-term expansions, blasts were repeatedly stimulated with anti-CD3/CD28 beads every 48 h during 8 days. Jurkat cells were maintained in culture after infection during 26 days. The proportions percentages of GFP 1 cells were determined by flow cytometry. Quantification of intracellular nucleotides. Intracellular pools of nucleotides were quantified based on previously described methods 32, 33 . Briefly, five million cells were washed in 0.1 M phosphate buffer (pH 7.4) and lysed in 60 ml HClO 4 1 M, containing 2 mM 8-bromo-AMP (8-BrAMP) as an internal standard. After 12,000g centrifugation for 5 min at 4 uC, supernatants were transferred to a 384-well plate and kept at 4 uC in an auto sampler before injection. Aliquots of 5 ml were injected onto a separation column (ACQUITY UPLC BEH300 C18, 1.7 mm, 2.1 3 100 mm reversed-phase column, Waters) with a flow rate of 0.5 ml min 21 and analysed with a tandem mass spectrometry system consisting of an Acquity Ultra Performance Liquid Chromatography (UPLC Waters) interfaced with a xevo-TQ-S tandem quadrupole mass spectrometer (Waters). Mobile phase A was 0.1% formic acid in water and mobile phase B, 0.1% formic acid in acetonitrile. A programmed mobile phase-gradient was used during a 7-min run: 0 min, 1% B; 5 min, 10% B; 5.1 min, 100% B; 6 min, 100% B; 6.1 min, 1% B; 7 min, 1% B. The content of the 4 nucleotides ATP, GTP, UTP and CTP was quantified in the electrospray negative ion mode with multiple reaction monitoring (MRM). Transitions of m/z 505.9 . 408 and 505.9 . 272.9 were used for quantification and confirmation of ATP, respectively, and those of 521.9 . 158.9 and 521.9 . 177 for GTP, 482.8 . 158.9 and 482.8 . 79 for UTP, and 481.8 . 158.9 and 481.8 . 384 for CTP. Concentrations were determined by using calibration curves of the 4 nucleotides. The linearity, exactitude and variability were determined for the technical validation of this assay. The linearity gave a correlation coefficient of the linear regression curves greater than 0.99 for the 4 nucleotides. The minimum and maximum recovery of spiked samples with the 4 nucleotides at a concentration of 90 mg l 21 and 250 mg l 21 ranged from 72% to 123%. The maximum intra-and inter-assay variability was 22% and 23%, respectively. Statistical analysis. P values were calculated with a Student's t-test using PRISM software (GraphPad Software), with a two-tailed distribution. The variance was similar between the groups that have been statistically compared. Histograms correspond to CFSE staining dilutions for which the number of cell divisions was indicated at the top of each peak. b, Proliferation of CD3 1 T and CD16 1 CD56 1 natural killer cells from PBMCs of a control donor (Ctr.) and a CTPS1-deficient patient (P1.2). Cells were stimulated with anti-CD3/CD28 coated beads for 3 days or IL-2 for 7 days. Representative dot plots showing cell divisions by dilution of the violet dye and expression of the activation marker CD69. Inserts with histograms showing the violet dye dilution with the number cell divisions indicated at the top of each peak.
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